TuisBNTX • NASDAQ
add
BioNTech SE - ADR
Vorige sluiting
$118,14
Dagwisseling
$118,01 - $121,34
Jaarwisseling
$76,53 - $131,49
Markkapitalisasie
28,71 mjd USD
Gemiddelde volume
673,46 k
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (EUR) | Sep. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 1,24 mjd | 39,04% |
Bedryfskoste | 1,04 mjd | 53,43% |
Netto inkomste | 198,10 m | 23,35% |
Netto winsgrens | 15,91 | -11,32% |
Wins per aandeel | 0,81 | 20,90% |
EBITDA | 65,30 m | -30,31% |
Effektiewe belastingkoers | -24,83% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (EUR) | Sep. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 16,71 mjd | 6,10% |
Totale bates | 22,40 mjd | 0,87% |
Totale aanspreeklikheid | 3,29 mjd | 40,43% |
Totale ekwiteit | 19,11 mjd | — |
Uitstaande aandele | 239,74 m | — |
Prys om te bespreek | 1,48 | — |
Opbrengs op bates | 0,23% | — |
Opbrengs op kapitaal | 0,27% | — |
Kontantvloei
Netto kontantverandering
| (EUR) | Sep. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | 198,10 m | 23,35% |
Kontant van bedrywe | -638,90 m | -178,76% |
Kontant van beleggings | -142,10 m | 88,47% |
Kontant van finansiering | -7,90 m | 97,46% |
Netto kontantverandering | -752,10 m | -12,12% |
Beskikbare kontantvloei | -684,45 m | -217,91% |
Meer oor
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
HUB
Gestig
2008
Webwerf
Werknemers
6 133
